Related Experiment Video

Updated: Aug 11, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Epidermal growth factor receptor (EGFR) inhibitors in gastrointestinal cancer

Teresa Macarulla1, Esther Casado, Francisco Javier Ramos

  • 1Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Onkologie
|March 4, 2006
PubMed

Insights

Gastrointestinal (GI) cancer treatments are improving with chemotherapy, but new strategies are needed. This review focuses on epidermal growth factor receptor (EGFR) inhibitors as a promising targeted therapy for GI cancers.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Gastrointestinal (GI) cancer remains a major global health challenge, causing significant morbidity and mortality.
  • Recent advancements in chemotherapy have improved treatment options for GI cancers.
  • There is an ongoing need for more effective and safer therapeutic strategies.

Purpose of the Study:

  • To review the current therapeutic strategies utilizing epidermal growth factor receptor (EGFR) inhibitors in the management of GI cancer.
  • To highlight the potential of targeted therapies in improving outcomes for GI cancer patients.

Main Methods:

  • Literature review of current research on EGFR inhibitors in GI cancer treatment.
  • Analysis of clinical data and therapeutic strategies involving EGFR inhibitors.
  • Discussion of the status and future directions of EGFR-targeted therapy.

Main Results:

  • Epidermal growth factor receptor (EGFR) inhibitors represent a significant advancement in targeted therapy for GI cancers.
  • These targeted inhibitors offer novel opportunities to improve treatment efficacy and safety.
  • The review synthesizes the current landscape of EGFR inhibitor application in GI oncology.

Conclusions:

  • Targeted inhibition of EGFR is a key emerging strategy in GI cancer treatment.
  • Further research and clinical application of EGFR inhibitors are crucial for enhancing patient outcomes.
  • EGFR inhibitors hold promise for improving the efficacy and safety of GI cancer therapies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: